Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Long-term Debt
Borrowings due after more than one year.
Citius Oncology, Inc.NASDAQ: CTOR
Long-term Debt · Q2 FY2026 · quarter ended Mar 2026
Long-term debt broadly unchanged from a year ago
Long-term debt stood at $3.8M at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.
Context
- Long-term debt amounted to 3.8% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term debt keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 3.8M USD
- Year-over-year change
- +0.0%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 3.8M | +0.0% |
| FY2024 | 2024-09-30 | 3.8M | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Long-term Debt vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 long-term debt of $3.8M is the 3rd highest of the 10 companies compared; the peer median is $507K.
- Its year-over-year change of +0.0% is the highest of 2, against a peer median of -49.3%.
- Long-term debt amounts to 3.8% of total assets for CTOR, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $72.05M | — | — | 25.3% | |
| Mar 2026 | $5.6M | — | — | 1.9% | |
CTORCitius Oncology, Inc. | Mar 2026 | $3.8M | +0.0% | — | 3.8% |
| Mar 2026 | $2.63M | — | — | 0.5% | |
| Mar 2026 | $1.95M | -49.3% | — | 2.2% | |
| Mar 2026 | $507K | — | — | 0.9% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K | — | +0.0% | 4.5% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTOR) | $507K | -49.3% | +0.0% | 0.9% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.